New antibody trial offers hope for Tough-to-Treat cancers
NCT ID NCT05518045
Summary
This study is testing a new antibody drug called LM-108, given alone or with other cancer treatments, in people with advanced solid tumors that have stopped responding to standard therapies. The main goals are to find a safe dose and see if the treatment can shrink tumors. It involves 392 participants and is currently in early-to-mid stage testing.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hospital
Beijing, China
Conditions
Explore the condition pages connected to this study.